Although apilimod was ineffective in clinical trials against Crohn’s disease and rheumatoid arthritis, the search for new PIKFYVE inhibitors, such as AS2677131 and AS2795440, to treat autoimmune and inflammatory diseases continues [120,123]. Here, PIKFYVE is linked to Crohn disease.